Lexeo Therapeutics (LXEO) Assets Average (2023 - 2026)
Lexeo Therapeutics recorded quarterly Assets Average of $259.5 million in Q1 2026, up 25.82% quarter-over-quarter from $206.3 million in Q4 2025, and up 90.38% year-over-year from $136.3 million in Q1 2025.
Lexeo Therapeutics' Assets Average history runs 4 years deep, the most recent figure standing at $259.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 90.38% year-over-year to $259.5 million; the TTM figure through Mar 2026 stood at $259.5 million (up 90.38% YoY), while the FY2025 annual figure was $207.8 million, up 44.95% from the prior year.
- Assets Average came in at $259.5 million for Q1 2026 at Lexeo Therapeutics, up from $206.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $259.5 million in Q1 2026 to a low of $97.3 million in Q4 2023.
- A 4-year average of $173.3 million and a median of $168.5 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average declined 25.53% in 2025 and soared 90.38% in 2026, its largest moves.
- Lexeo Therapeutics' Assets Average stood at $97.3 million in 2023, then surged by 64.91% to $160.4 million in 2024, then advanced by 28.59% to $206.3 million in 2025, then grew by 25.82% to $259.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $259.5 million, $206.3 million, and $160.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | 259.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259.52 Mn |
| Dec 31, 2025 | 206.27 Mn |
| Sep 30, 2025 | 159.96 Mn |
| Jun 30, 2025 | 150.88 Mn |
| Mar 31, 2025 | 136.32 Mn |
| Dec 31, 2024 | 160.40 Mn |
| Sep 30, 2024 | 182.94 Mn |
| Jun 30, 2024 | 202.61 Mn |
| Mar 31, 2024 | 176.51 Mn |
| Dec 31, 2023 | 97.27 Mn |